howitreat.in
A user-friendly, frequently updated reference guide that aligns with international guidelines and protocols.
News & Updates
Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML
This retrospective study assessed the efficacy and safety of the venetoclax-homoharringtonine-cytarabine (VHA) regimen in 55 patients with newly diagnosed acute myeloid leukemia. The overall response rate was 92.7%, with a composite complete remission rate of 87.3%, and 85.4% of patients achieving MRD-negative complete remission. In the adverse-risk subgroup, response rates remained high, with manageable toxicity—main grade 3–4 adverse events being febrile neutropenia, pneumonia, and sepsis. The VHA regimen showed promising survival outcomes, with a median overall survival of 26 months and a one-year overall survival of 83%, indicating strong potential for further investigation.
Pathophysiology
Myeloproliferative neoplasms and related disorders
Myelodysplastic Neoplasms and related disorders
Acute Leukemias
Hodgkin and Non Hodgkin lymphoma
Mature B Cell Neoplasms
Mature T Cell and NK Cell neoplasms
Anemias
Coagulation disorders
Platelet Disorders
Missellaneous Diseases and consultative hematology
Emergencies and Supportive Care
Drug Doses and Precautions
Stem Cell Transplantation
Other Hematology Topics
An Initiative of
Veenadhare Edutech Private Limited
1299, 2nd Floor, Shanta Nivas,
Beside Hotel Swan Inn, Off J.M.Road, Shivajinagar
Pune - 411005
Maharashtra – India
howitreat.in
CIN: U85190PN2022PTC210569
Email: admin@howitreat.in
Disclaimer: Information provided on this website is only for medical education purposes and not intended as medical advice. Although authors have made every effort to provide up-to-date information, the recommendations should not be considered standard of care. Responsibility for patient care resides with the doctors on the basis of their professional license, experience, and knowledge of the individual patient. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse effects, please refer to the approved product label. Neither the authors nor publisher shall be liable or responsible for any loss or adverse effects allegedly arising from any information or suggestion on this website. This website is written for use of healthcare professionals only; hence person other than healthcare workers is advised to refrain from reading the content of this website.